|
|
 |
|
Viewing report
|
|
|
|
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Arrowhead Publishers, Aug 2008, Pages: 318
Objectives and Scope
The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail the markets for colorectal cancer, prostate cancer, lung cancer, breast cancer, leukemia and non-Hodgkin’s lymphoma. Therapies for other types of cancer are discussed throughout the report, but are limited to the Company Briefs chapter and various tables throughout the report. This report from Arrowhead Publishers examines these major cancer markets in light of newly emerging therapeutics, shifting market shares and line extensions for major products on the market.
Reason for this study
The overall economic cost of cancer is staggering. The US National Institutes of Health (NIH) estimates overall costs of cancer in the U.S. in 2006 at $206.3 billion with $78.2 billion in direct medical costs. Further the WHO predicts that global cases of cancer will rise to 15 million new cases by 2020, an increase of 50% over 2005’s rate. These staggering numbers indicate the importance of effective therapies in treating this epidemic. There is today still a strong need for therapies that
- more specifically target cancer cells
- extend progression-free survival rates
- provide patients with metastatic cancer better treatment options
-
What questions does this report answer
- What is the current market status of cancer therapeutics in general and with regard to specific types of cancer?
- What are the strengths, weaknesses, opportunities and threats facing various cancer therapeutics already on the market and ones still in the clinic?
- What are the major issues involved in the research and development of more effective cancer therapeutics?
- Which new cancer therapeutics in development are nearing the market? And how are they performing in the clinic?
Key features of this Report
- Market analysis of cancer therapeutics, by product, class, cancer type, region/country and company
- SWOT (strengths, weaknesses, opportunities, threats) analysis for key products on the market as well as for key emerging products
- A thorough overview of treatment regimens for various cancers, including detailed information and analysis of first-line, second-line and third-line treatment options
- Financial forecasts, by individual cancer therapy and cancer type
- Explanations of key technologies and mechanism of action of new classes of cancer drugs
- Thorough descriptions of important areas of research and development in cancer therapeutics and cancer vaccines
- Focused analysis of the global prevalence of cancer: incidence, mortality and survival rates as they relate to new directions in cancer research
- Company briefs of stakeholders and companies active in cancer therapy R&D
- Over 145 tables/graphs analyzing the current and future market, disease incidence and R&D pipelines for cancer therapeutics
- Presentation and analysis of clinical data underscoring success of key therapies
- Market share data for leading companies and products in the field
- Profiles of leading products in the major cancer markets and analysis of their market impact
Customers who bought this item also bought
Prostate Cancer - A Therapeutic & Competitive Insight
Innovations in Cancer: Novel Therapeutics, New Diagnostics and Future R&D Strategies
Analytical Tool - Prostate Cancer: A Therapeutic & Competitive Insight
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Innovative Drug R&D in China
Triple Analysis: Decoding Big Pharma's R&D Strategy In Oncology and Special Focus on Breast and Prostate Cancer
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma - Limited R&D Activity Provides Opportunity for Early-Phase Pipeline Drugs
Forecast Insight: Osteoarthritis
|
|
|
|
